Transdermal fentanyl for cancer pain

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Hadley, Gina ^a   Derry, Sheena ^a   Moore, R Andrew ^a   Wiffen, Philip J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COCODAMOL; FENTANYL; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT;

ABDOMINAL PAIN; ANALGESIA; CANCER PAIN; CONFUSION; CONSTIPATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; NAUSEA; PAIN ASSESSMENT; PAIN INTENSITY; PAIN SEVERITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COMPLICATION; INTRADERMAL DRUG ADMINISTRATION; META ANALYSIS; NEOPLASM; PAIN; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; FENTANYL; HUMANS; METHADONE; MORPHINE; NEOPLASMS; PAIN; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84893974862     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010270.pub2     Document Type: Review

References (40)

1. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. Journal of Pain and Symptom Management 1997;13(5):254-61. [DOI: 10.1016/S0885-3924(97)00082-1]
2. Kongsgaard UE, Poulain P. Transdermal fentanyl for pain control in adults with chronic cancer pain. European Journal of Pain 1998;2(1):53-62.
3. Kress HG, Von der Laage D, Hoerauf KH, Nolte T, Heiskanen T, Petersen R, et al.A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. Journal of Pain and Symptom Management 2008;36(3):268-79. [DOI: 10.1016/j.jpainsymman.2007.10.023]
4. Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, et al.Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain 2008;12(8):1040-6. [DOI: 10.1016/j.ejpain.2008.01.013]
5. Mystakidou K, Katsouda E, Kouloulias V, Kouvaris J, Tsiatas M, Vlahos L. Comparison of transdermal fentanyl with codeine/paracetamol, in combination with radiotherapy, for the management of metastatic bone pain. Journal of Opioid Management 2005;1(4):204-10.
6. Oztürk T, Karadibak K, Catal D, Cakan A, Tugsavul F, Cirak K. Comparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer. Agri 2008;20(3):20-5.
7. Pistevou-Gompaki K, Kouloulias VE, Varveris C, Mystakidou K, Georgakopoulos G, Eleftheriadis N, et al.Radiotherapy plus either transdermal fentanyl or paracetamol and codeine for painful bone metastases: a randomised study of pain relief and quality of life. Current Medical Research and Opinion 2004;20(2):159-63. [DOI: 10.1185/030079903125002829]
8. van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Current Medical Research and Opinion 2003;19(6):457-69. [DOI: 10.1185/030079903125002045]
9. Wong JO, Chiu GL, Tsao CJ, Chang CL. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiologica Sinica 1997;35(3):25-32.
10. Ergenoglu P, Ozbek H, Gunduz M, Isik G. Comparison of the analgesic efficacy of intravenous morphine infusion and transdermal fentanyl in oncology patients with mucositis [Mukozitli onkoloji hastalarinda intravenoz morfin infuzyonu ve transdermal fentanilin analjezik etkinliginin karsilastirilmasi]. Anatolian Journal of Clinical Investigation 2010;4(3):134-40.
11. Sarhan T, Doghem M. A comparison of two trans-dermal drug delivery systems; buprenorphine and fentanyl for chronic cancer pain management. European Journal of Pain. 6th Congress of the European Federation of IASP Chapters: Pain in Europe 6th, EFIC Lisbon Portugal. 2009; Vol. 13:S199.
12. Wirz S, Wittmann M, Schenk M, Schroeck A, Schaefer N, Mueller M, et al.Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. European Journal of Pain 2009;13(7):737-43. [DOI: 10.1016/j.ejpain.2008.09.005]
13. Cachia E, Ahmedzai SH. Transdermal opioids for cancer pain. Current Opinion in Supportive and Palliative Care 2011;5(1):15-9. [DOI: 10.1097/SPC.0b013e3283437a39]
14. Cancer Research UK. Cancer incidence for all cancers combined. http://info.cancerresearchuk.org/cancerstats/incidence/all-cancers-combined/ [Accessed 22 May 2013].
15. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, et al.Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Current Medical Research and Opinion 2004;20(9):1419-28. [DOI: 10.1185/030079904X2114]
16. Cleary JF. The pharmacologic management of cancer pain. Journal of Palliative Medicine 2007;10(6):1369-94. [DOI: 10.1089/jpm.2007.9842]
17. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310(6977):452-4.
18. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al.Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
19. Durogesic® DTrans. http://www.medicines.org.uk/EMC/medicine/17088/ (Accessed 22 May 2013).
20. Hadley G, Derry S, Moore RA, Wee B. Can observational studies provide a realistic alternative to randomized controlled trials in palliative care?. Journal of Pain & Palliative Care Pharmacotherapy 2009;23(2):106-13. [DOI: 10.1080/15360280902899921]
21. Heiskanen T, Mätzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain 2009;144(1-2):218-22. [DOI: 10.1016/j.pain.2009.04.012]
22. Altman DG, Antes G, Gøtzsche P, Higgins JPT, Jüni P, Lewis S, et al.Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
23. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12. [DOI: 10.1016/0197-2456(95)00134-4]
24. Jeal W, Benfield P. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997;53(1):109-38.
25. Kornick CA, Santiago-Palma J, Moryl N, Payne R, Obbens EA. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Safety 2003;26(13):951-73.
26. Koyyalagunta D, Bruera E, Solanki DR, Nouri KH, Burton AW, Toro MP, et al.A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 2012;15(3 Suppl):ES39-58.
27. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107(2):224-33.
28. Lehmann KA, Zech D. Transdermal fentanyl: clinical pharmacology. Journal of Pain and Symptom Management 1992;7 3 Suppl:S8-16.
29. Marinangeli F, Ciccozzi A, Aloisio L, Colangeli A, Paladini A, Bajocco C, et al.Improved cancer pain treatment using combined fentanyl-TTS and tramadol. Pain Pract 2007;7(4):307-12. [DOI: 10.1111/j.1533-2500.2007.00155.x]
30. McQuay H, Moore R. An evidence-based resource for pain relief. An evidence-based resource for pain relief. Oxford: Oxford University Press, 1998. [ISBN: 0-19-263048-2]
31. Moore RA, Bullingham RE, McQuay HJ, Hand CW, Aspel JB, Allen MC, et al.Dural permeability to narcotics: in vitro determination and application to extradural administration. British Journal of Anaesthetics 1982;54(10):1117-28.
32. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]
33. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]
34. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG editors editor(s). Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: BMJ Books, 1995:50-63.
35. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001;61(15):2289-307.
36. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
37. Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P, et al.Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. Journal of Palliative Medicine 2008;11(3):492-501. [DOI: 10.1089/jpm.2007.0200]
38. Tassinari D, Drudi F, Rosati M, Maltoni M. Transdermal opioids as front line treatment of moderate to severe cancer pain: a systemic review. Palliative Medicine 2011;25(5):478-87. [DOI: 10.1177/0269216311404274]
39. Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ. Impact of covert duplicate results on meta-analysis: a case study. BMJ 1997;315(7109):635-40.
40. Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD003868.pub3]